Core Viewpoint - Myriad Genetics, Inc. will hold its fourth quarter and full year 2024 earnings conference call on February 24, 2025, providing a financial overview and business update [1] Upcoming Investor Conferences - Management will participate in three upcoming investor healthcare conferences: - TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 9:50 am ET [4] - Raymond James 46th Annual Institutional Investors Conference on March 4, 2025, at 4:00 pm ET [4] - Leerink Global Healthcare Conference on March 10, 2025, at 2:20 pm ET [4] Company Overview - Myriad Genetics is a leader in genetic and genomic tumor testing and precision medicine, focusing on advancing health and well-being [3] - The company develops genetic tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [3]

Core Insights - Myriad Genetics, Inc. has entered an agreement to enhance education and access to hereditary cancer testing for CancerCARE for Life members, allowing over 1 million individuals to assess their eligibility for the MyRisk test [1][2] - The collaboration aims to strengthen Myriad's Hereditary Cancer testing business, which has been recognized for its significant advances in genomic medicine [2][3] Company Developments - Myriad Genetics' shares experienced a decline of 1.5% following the announcement of the collaboration [3] - The MyRisk Hereditary Cancer Test has been gaining synergies, and it was named one of the top 10 significant advances in genomic medicine by the American Journal of Human Genetics in December 2024 [3][4] - The company has a market capitalization of $1.13 billion and a long-term EPS growth rate of 44%, significantly higher than the industry average of 20% [4] Product Information - MyRisk with RiskScore is the first industry-leading hereditary cancer test that evaluates 48 genes associated with hereditary cancer risk for 11 different cancers [5] - The test provides a five-year and remaining lifetime breast cancer risk assessment when combined with family history and other clinical factors [5] Industry Outlook - The global hereditary cancer testing market was valued at $3.5 billion in 2021 and is projected to grow at a compound annual growth rate of 11.6% through 2031, driven by an increasing geriatric population and rising cancer incidence [8] - The collaboration with CancerCARE is expected to enhance market sentiment towards Myriad Genetics' stock [4] Additional Collaborations - In January, Myriad Genetics partnered with sports broadcaster Hannah Storm, who will serve as an ambassador for the Breast Cancer Risk Assessment Program [9]

Core Insights - Myriad Genetics, Inc. has partnered with INTERLINK Care Management to improve education and access to hereditary cancer testing for CancerCARE for Life members [1][4] - The agreement allows over one million individuals in CancerCARE's network to evaluate their eligibility for the MyRisk test through the MyGeneHistory quiz [2][3] Company Overview - Myriad Genetics is a leader in genetic and genomic tumor testing and precision medicine, focusing on advancing health and well-being through genetic insights [6] - The company offers the MyRisk with RiskScore Hereditary Cancer Test, which evaluates 48 genes linked to hereditary cancer risk and provides personalized risk assessments for various cancers [3][4] Industry Context - CancerCARE for Life is one of the largest cancer prevention and management programs in the U.S., combining education with personalized care to enhance member experiences [5] - The collaboration aims to increase access to genetic screening, enabling patients to make informed decisions regarding their health [4][5]

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad’s ability to bring its tumor-informed, high-definition, molecular residual disease (MRD) assay to market. US patent No. 12,215,391 relates to Myriad’s proprietary automated methods of MRD analysis. Specifically, the claims are relevant to ...

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests — Prolaris® Prostate Cancer Test and MyRisk® Hereditary Cancer Test – into Lumea’s digital pathology platform, BxLink™. This collaboration will streamline the ordering and delivery of molecular tests, enabling heal ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company's "Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation" study was awarded SMFM's "Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics." The study found that ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company’s “Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation” study was awarded SMFM’s “Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics.” The study found that ...

Myriad Genetics, Inc. (MYGN) recently launched a new educational website, Know More Sooner, which provides comprehensive information about reproductive and prenatal genetic testing. The latest launch should bolster the company’s Prenatal business. MYGN Stock Movement Following the NewsFollowing the news, shares of MYGN rose 3.9% to $12.76 yesterday. According to a survey, the majority of women wanted prenatal screening once they understood how genetic testing can provide insights into their pregnancy’s gene ...

Core Insights - Myriad Genetics has launched a new educational website, "Know More Sooner," aimed at providing comprehensive information about reproductive and prenatal genetic testing [1][2] Group 1: Website Features and Purpose - The "Know More Sooner" website aims to educate users on the benefits of prenatal genetic testing, dispel myths, and provide guidance on screening locations and actions for high-risk results [2] - The site includes real-life patient stories to demonstrate how prenatal screening can assist parents in managing their pregnancies [2] Group 2: Survey Insights - A survey indicated that many women desire prenatal screening once they understand its benefits, yet 40% of respondents reported not being offered noninvasive prenatal testing (NIPT) [3] - The survey was conducted with 1,000 US-based individuals who identified as pregnant or recently pregnant [6] Group 3: Recommendations and Expert Opinions - The American College of Obstetricians and Gynecologists (ACOG) recommends that carrier and cfDNA screening be offered to all pregnant patients, regardless of ancestry, maternal age, or risk of chromosomal abnormalities [4] - Experts from Myriad Genetics emphasize the importance of understanding genetic testing benefits to help women make informed decisions during pregnancy [5] Group 4: Genetic Tests Offered - Myriad Genetics offers three genetic tests for pregnant individuals: - SneakPeek Gender Test, which predicts fetal sex as early as six weeks with over 99% accuracy [8] - Foresight Carrier Screen, identifying risks of passing down serious inherited conditions [8] - Prequel Prenatal Screen, assessing risks for various chromosomal conditions as early as eight weeks [8]

Core Insights - A study by Myriad Genetics demonstrated that the use of an online screening tool and patient education significantly increased the completion rate of hereditary cancer testing among patients [1][2][8] Group 1: Study Findings - The implementation of MyGeneHistory, an online patient screening tool, led to a 30% increase in the identification of patients meeting guidelines for hereditary cancer testing (HCT) [8] - There was a 50% increase in the number of patients who met the guidelines and were offered HCT [8] - More than twice the number of patients completed HCT after the introduction of the online tool and education program [8] Group 2: Clinical Impact - Clinicians reported increased confidence in administering hereditary cancer risk assessments, with 87% stating that the online tools helped them adhere to recommended standards of care [3] - Over 80% of providers believed the program assisted them in following ACOG guidelines for hereditary cancer risk assessment [3] Group 3: Program Details - Myriad's Breast Cancer Risk Assessment Program includes the MyRisk with RiskScore Hereditary Cancer Test and the MyGeneHistory online screening tool, which assesses if a patient meets medical guidelines for hereditary cancer testing [5] - The program also provides patient education on genetic testing and guidance on collecting family history related to certain cancers [5] Group 4: Study Overview - The study involved over 10,000 patients across five U.S. community obstetrics/gynecology practices, with an eight-week observation period followed by training on the online screening and education program [6]